85 related articles for article (PubMed ID: 22872931)
61. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.
Bunni J; Shelley-Fraser G; Stevenson K; Oltean S; Salmon A; Harper SJ; Carter JG; Bates DO
Am J Cancer Res; 2015; 5(6):2083-9. PubMed ID: 26269767
[TBL] [Abstract][Full Text] [Related]
62. The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study.
Dogan M; Demirkazik A; Konuk N; Yalcin B; Buyukcelik A; Utkan G; Tek I; Akbulut H; Sencan O; Icli F
Int J Biol Markers; 2006; 21(4):206-210. PubMed ID: 28207147
[TBL] [Abstract][Full Text] [Related]
63. Expression of angiogenic growth factors in laryngeal carcinoma.
Korampalli TS; Stafford ND
Mol Clin Oncol; 2013 Nov; 1(6):1013-1018. PubMed ID: 24649286
[TBL] [Abstract][Full Text] [Related]
64. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.
Kut C; Mac Gabhann F; Popel AS
Br J Cancer; 2007 Oct; 97(7):978-85. PubMed ID: 17912242
[TBL] [Abstract][Full Text] [Related]
65. Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.
Corvigno S; Frödin M; Wisman GBA; Nijman HW; Van der Zee AG; Jirström K; Nodin B; Hrynchyk I; Edler D; Ragnhammar P; Johansson M; Dahlstrand H; Mezheyeuski A; Östman A
J Pathol Clin Res; 2017 Jul; 3(3):214-224. PubMed ID: 28770105
[TBL] [Abstract][Full Text] [Related]
66. Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer.
Ilson DH
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):200-201. PubMed ID: 34998470
[No Abstract] [Full Text] [Related]
67. Right-side cardiac metastasis of squamous cell carcinoma from oesophagogastric junction cancer.
Matsumoto H; Ijuin S; Terashi T
Eur Heart J Case Rep; 2024 Jun; 8(6):ytae294. PubMed ID: 38912117
[No Abstract] [Full Text] [Related]
68. Investigating the predictive value of vascular endothelial growth factor in the evaluation of treatment efficacy and prognosis for patients with non-surgical esophageal squamous cell carcinoma.
Kong Z; Sun F; Meng Q; Zhou M; Yu J; Hu L
Front Oncol; 2022; 12():843250. PubMed ID: 36387083
[TBL] [Abstract][Full Text] [Related]
69. Circulating vascular endothelial growth factor and cancer risk: A bidirectional mendelian randomization.
Wu H; Ma T; Li D; He M; Wang H; Cui Y
Front Genet; 2022; 13():981032. PubMed ID: 36159967
[TBL] [Abstract][Full Text] [Related]
70. The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.
Quốc Lu'o'ng KV; Nguyễn LT
Cancer Manag Res; 2012; 4():431-45. PubMed ID: 23293538
[TBL] [Abstract][Full Text] [Related]
71. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer.
McDonnell CO; Harmey JH; Bouchier-Hayes DJ; Walsh TN
Br J Surg; 2001 Aug; 88(8):1105-9. PubMed ID: 11488797
[TBL] [Abstract][Full Text] [Related]
72. Prognostic markers in esophageal cancer: from basic research to clinical use.
Hong L; Han Y; Zhang H; Fan D
Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):887-9. PubMed ID: 26067755
[TBL] [Abstract][Full Text] [Related]
73. Quantification of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer: a long-term follow-up study.
Gray RT; O'Donnell ME; McGuigan JA; Spence GM
Br J Biomed Sci; 2012; 69(2):71-5. PubMed ID: 22872931
[TBL] [Abstract][Full Text] [Related]
74. Long-term follow-up of immunocytochemical analysis of vascular endothelial growth factor (VEGF), and its two receptors, VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1/KDR), in oesophagogastric cancer.
Gray RT; O'Donnell ME; Maxwell P; McGuigan JA; Spence GM
Int J Biol Markers; 2013 Apr; 28(1):63-70. PubMed ID: 23250775
[TBL] [Abstract][Full Text] [Related]
75. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
76. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
